M. Parry Billings (St Albans, United Kingdom), O. Usmani (London, United Kingdom)
Investigation of Beclason efficiency in new delivery device Easi-breathe
Y. M. Dityatkovskaya, O. V. Shporta (Dniepropetrovsk, Ukraine)
|  |
Fine particle mass of salbutamol: diskus and turbuhaler in vitro compared
M. Broeders, J. Molema, N. Vermue, P. Burnell, H. Folgering (Groesbeek, The Netherlands; , United Kingdom)
| |
In vitro delivery of an HFA-based corticosteroid by pediatric and adult valved holding chambers (VHC): effect of inhalation flow rate
M. W. Nagel, S. L. Bates, J. P. Mitchell (London, Canada)
| |
Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children
T. Vanto, K. M. Hämäläinen, M. Vahteristo, S. Wille, F. Njå, N. Hyldebrand (Turku, Kuopio, Finland; Helsingborg, Sweden; Sandvika, Norway; Odense, Denmark)
| |
Comparison of two valved holding chambers for the delivery of an HFA-based solution corticosteroid formulation
M. W. Nagel, C. C. Doyle, S. L. Bates, J. P. Mitchell (London, Canada)
| |
Effect of salmeterol diskus (S) and formoterol turbuhaler (F) on pulmonary arterial pressure (PAP) in patients with COPD
M. Cazzola, A. Mantero, P. Santus, P. Carlucci, M. Mondoni, C. Bencini, S. Centanni (Naples, Milan, Italy)
| |
Nebulized salbutamol through the ultrasonic nebulizer during sputum induction improves the bronchoprotection in asthmatics
P. P. Kange, M. E. Henket, P. P. Bartsch, R. E. Louis (Liege, Belgium)
| |
Aerosolized bechlometasone dipropionate (BDP) delivered via TNI® vesicles: a new approach for the treatment of asthmatic and COPD patients
C. Terzano, M. Carafa (Roma, Chieti, Italy)
| |
Deposition of Foradil P in the human lungs- comparison of in-vitro data and in-vivo data
T. Weuthen, S. Häußermann, T. Meyer, J. Brauburger, G. Scheuch (Gauting, Nürnberg, Germany)
| |
Formoterol 6 μg and 12 μg delivered via a new multi-dose dry powder inhaler has a rapid onset of action with a duration of at least 12 hours
V. Vondra, G. K. Terpstra, Czech Republic Aimax Study Group (Prague, Czech Republic; Leiderdorp, The Netherlands)
| |
Formoterol delivered via a new multi-dose dry powder inhaler is safe and efficacious in adolescents aged 12-18 years
V. M. Revyakina, G. K. Terpstra, Russia Airmax Study Group (Moscow, Russia; Leiderdorp, The Netherlands)
| |
Salbutamol delivered via a new multi-dose dry powder inhaler is as safe and efficacious as a pressurised metered dose inhaler in children aged 6-12 years
V. R. Revyakina, G. K. Terpstra, Russia Airmax Study Group (Moscow, Russia; Leiderdorp, The Netherlands)
| |
Dose response to budesonide using adenosine monophosphate (AMP) bronchial challenge: assessment of two dry powder inhalers
E. J. Sims, M. C. Patterson, S. K. Das, H. B. Buck, B. J. Lipworth (St Albans, United Kingdom)
| |
Comparison of the acceptability of dry powder inhalers. A meta-analysis based on international data
M. Koivumäki, M. Vahteristo (Espoo, Kuopio, Finland)
| |
Physicians in the United States and the United Kingdom show a preference for mometasone furoate dry powder inhaler over other inhalers
J. P. Karpel, G. Rachelefsky, J. E. Harrison (Bronx, Los Angeles, Kenilworth, United States Of America)
| |
Effect of QVAR® on inflammatory cells and cytokine gene expression in early and late sputum samples in asthmatics
R. Taha, H. P. Hauber, V. Migoumov, Q. A. Hamid, R. Olivenstein (Montreal, Canada)
| |
Technique: the usual problem of metered dose inhalers
G. A. Pinheiro, V. C. S. Antao, J. M. Jansen (Rio de Janeiro, Brazil)
| |
Correct use of meter dose inhaler device in relation to patient care, symptoms and disease exacerbations
P. N. Teh, L. C. Loh (Kuala Lumpur, Malaysia)
| |
The effectiveness and safety of pre-hospital nebulizer therapy of elderly patients with bronchial asthma
A. L. Vertkin, L.S. Namazova, F. A. Vilkovyssky, V. L. Barataschvily, E. V. Krivtsova, N. V. Vaganova (Moscow, Russia)
| |